Communiqués Myriad Genetics, Inc.

Actions

MYGN

US62855J1043

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX Autres places de cotation 19:00:56 13/07/2026			Varia. 5j.	Varia. 1 janv.
5,980 ^USD	+2,57 %		-0,83 %	-2,76 %

02/07	Myriad Genetics publie une méta-analyse à grande échelle démontrant la performance pronostique du test de biopsie Prolaris dans le cancer de la prostate localisé	CI
23/06	Myriad Genetics, Inc. annonce la démission de Daniel M. Skovronsky de son poste d’administrateur, avec effet au 17 juin 2026	CI

Communiqués

02/07	New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer	GL
23/06	Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication	GL
02/06	Myriad Genetics Names Raj Jampa as New Chief Technology Officer	GL
27/05	Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting	GL
26/05	Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)	GL
15/05	Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life	GL
08/05	Myriad Genetics : to Participate in Upcoming Investor Healthcare Conferences	PU
07/05	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences	GL
05/05	Myriad: Q1 Earnings Snapshot	AQ
05/05	Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business	GL
01/05	Myriad Genetics National Survey, 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan	AQ
30/04	Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan	GL
28/04	Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026	GL
16/04	Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026	GL
14/04	Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan	GL
14/04	Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan	AQ
09/04	Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting	GL
17/03	Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer	GL
02/03	Myriad Commercially Launches Precise MRD with Select Community Oncologists	GL
24/02	Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests	GL
23/02	Myriad: Q4 Earnings Snapshot	AQ
23/02	Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution	GL
19/02	FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test	GL
16/02	Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026	GL
27/01	Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data	GL